Could a daily aspirin boost ovarian cancer treatment?
NCT ID NCT05080946
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goal is to see if aspirin makes the tumor more vulnerable to the immune system, potentially improving treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin (325 mg daily)
What this could lead to
If it works, this could point toward a way to make standard chemotherapy more effective for ovarian cancer by reducing immune suppression in the tumor.
What could go wrong
This is a very early, small pilot study (Phase 1) looking at immune markers, not survival. Aspirin may not change tumor immune features, and results may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Schar Cancer Institute
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact